Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOXA Continue: Continuous vs Intermittent Cloxacillin in MSSA Bone and Joint Infections
NCT03246360Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Nov 2017
- Primary completion
- Nov 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of cloxacillin in Bone and osteoarticular infections (BJI) and Staphylococcus aureus infection (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Time above minimal inhibitory concentration at 6 days and Area under the curve to minimal inhibitory concentration ratio at 6 days. Started Nov 2017; status: completed.
02
Drugs
cloxacillin
03
Conditions
Bone and osteoarticular infections (BJI)Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03246360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246360.